- Previously reported study demonstrated clinically meaningful efficacy with a favorable safety profile for TMB-001 in moderate to severe congenital...
Shares will Trade on Nasdaq Capital Market under Ticker Symbol “PXMD” TARRYTOWN, NY, Aug. 26, 2022 (GLOBE NEWSWIRE) -- via...
LITTLETON, Colo., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”) today announced that...
Lab Reaching Out to Georgia-based School Administrators to Assist with Outbreak PlansNEW YORK, NY and TEL AVIV, Israel, Aug. 26,...
Study represents first data with BCX9930 in C3G patientsRESEARCH TRIANGLE PARK, N.C., Aug. 26, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals,...
- 141 MDS Patients Enrolled -- Topline Data Anticipated 1H:2023 - SAN FRANCISCO, Aug. 26, 2022 (GLOBE NEWSWIRE) -- FibroGen,...
-Results featured in a late-breaking oral presentation- -Treatment with pegozafermin demonstrated consistent and significant benefit in triglyceride (TG) reduction as...
Oslo, Norway, 26 August 2022 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's first-half year...
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 26 August 2022 – 8AM CET Disclosure of received notification from The Goldman Sachs Group,...
Louvain-La-Neuve, Belgium, 26 August, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s...
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company addressing tumor recurrence through cell-based immunotherapies, today announces that it has entered...
-- the 7th innovative drug in Junshi Biosciences’ pipeline to get IND approval from the US FDASHANGHAI, China, Aug. 25,...
TORONTO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA), the Canadian parent of...
Deals position Optimi Life nutraceutical brand for international distribution Optimi Life Optimi Life Bundle Optimi Life Optimi Life Optimi Life...
PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on...
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”)...
Abelacimab is the only Factor XI inhibitor currently being evaluated in Phase 3 trials The MAGNOLIA study will compare abelacimab...
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock...
Ublituximab is an investigational targeted B-cell therapy that shows superior efficacy when compared with teriflunomide, a commonly prescribed oral treatment...
Patient denied testing for weeks due to risk of physician infection & non-MSM status Amerimmune Long COVID Panel and Provista...